Microsoft Drafts Consumers In Fight Against Software Piracy: Carrot And Stick 06/12/2009 by Monika Ermert for Intellectual Property Watch 1 Comment US software giant Microsoft said Thursday that users globally have started to join the fight against software piracy by sending in over 150,000 reports about problems with fake Microsoft products over the last two years.
Conférence de Copenhague: incertitude sur les droits de propriété intellectuelle 13/11/2009 by Catherine Saez, Intellectual Property Watch 1 Comment BARCELONE – Les négociations sur le climat se sont achevées le 6 novembre après une semaine de discussions. Malgré les assurances données par la plupart des délégations sur le fait que tout était possible lors de la Conférence de Copenhague sur le changement climatique qui aura lieu en décembre, l’incertitude demeure sur de nombreuses questions qui concernent notamment le financement, la réduction des émissions de gaz à effet de serre, le transfert de technologie et la nature de l’accord qui sera conclu à Copenhague.
Pour les experts, l’accès à des médicaments sûrs est une question de santé publique et non de propriété intellectuelle 15/10/2009 by Catherine Saez, Intellectual Property Watch 1 Comment Selon les participants à un récent événement organisé par Open Society Institute, les initiatives de lutte contre la contrefaçon pourraient limiter l’accès aux traitements sans pour autant réduire le problème des médicaments contrefaits, en particulier dans les pays en développement.
专家组：获取安全药品是公共卫生问题而非知识产权问题 15/10/2009 by Catherine Saez, Intellectual Property Watch Leave a Comment 在最近由开放社会协会（Open Society Institute）主办的一次会议上，与会专家表示，反假冒倡议可能阻碍人们获得药品，但无法解决假药问题，在发展中国家尤其如此。
Grupo de expertos considera que el acceso a los medicamentos seguros es una cuestión de salud pública y no de propiedad intelectual 14/10/2009 by Catherine Saez, Intellectual Property Watch Leave a Comment Las iniciativas de lucha contra la falsificación podrían dificultar el acceso a los medicamentos sin que se logre paliar el problema de los fármacos falsificados, en particular en los países en desarrollo, según dijeron miembros de un grupo de expertos en un evento organizado recientemente por el Open Society Institute.
Access To Safe Medicine A Public Health Issue, Not IP, Says Panel 04/10/2009 by Catherine Saez, Intellectual Property Watch 2 Comments Anti-counterfeiting initiatives might have a negative impact on access to medicines while not addressing the problem of fake medicines, particularly in developing countries, according to panellists at a recent event organised by the Open Society Institute.
Third Revision of Patent Law in China (Part II) 01/10/2009 by Intellectual Property Watch 4 Comments The third amendment of Chinese Patent Law enters into force from 1 October, 2009. This article by Wenting Cheng explores the major changes in substantive requirements for patent grant, post-grant enforcement and adaptation of Chinese Patent Law to international norms on the protection of intellectual property.
Third Revision Of Patent Law In China 08/09/2009 by Intellectual Property Watch 5 Comments The third amendment of China’s patent law will enter into force from 1 October, 2009. In this article, Wenting Cheng explores the major changes in substantive requirements for patent grant, post grant enforcement and adaptation of Chinese patent law to international norms on the protection of intellectual property.
Novartis Persists In Challenge To Indian Patent Law; India Rejects More AIDS Drugs Patents 02/09/2009 by Robinson Esalimba for Intellectual Property Watch 5 Comments Undeterred by two previous decisions by Indian authorities holding that under Indian Patent Law, its leukaemia drug – Gleevec is not patentable, Novartis now wants to take the fight to the Indian Supreme Court. Meanwhile, also this week, sources say Indian authorities rejected applications for patents on two HIV/AIDS drugs, opening the way for cheaper generic versions to be developed and marketed.
Indian High Court Rejects Bayer Complaint For Patent Linkage 21/08/2009 by Monika Ermert for Intellectual Property Watch and Kaitlin Mara for Intellectual Property Watch 3 Comments Indian generics manufacturer Cipla can get marketing approval for its generic cancer treatment Soranib, the Delhi High Court ruled Tuesday, and the Indian drug regulatory authority does not have to check its patent status first. The court this week rejected a complaint by drug multinational Bayer against the Union of India, the Drug Controller General of India and generic drug producer Cipla. Bayer sought a court order requiring DCGI to consider the patent status of kidney cancer drug, sorafenib tosylate (sold under the brand name Nexavar), before granting marketing approval for a generic version of the drug. At issue was whether it is legitimate to link a potential violation of IP rights to processes regulating a drug’s entry onto the market that are generally based on drug quality, efficacy and safety.